We have previously identified an oncogenic role of artemin (ARTN), a member of glial cell derived neurotrophic factor family of ligands, in mammary carcinoma. We herein report that ARTN is an estrogen-inducible gene. Metaanalysis of gene expression data sets showed that ARTN expression is positively correlated to estrogen receptor (ER) status in human mammary carcinoma. Furthermore, in patients with ER-positive mammary carcinoma treated with tamoxifen, high ARTN expression is significantly correlated with decreased survival. Forced expression of ARTN in ER-positive human mammary carcinoma cells increased ER transcriptional activity, promoted estrogenindependent growth and produced resistance to tamoxifen and fulvestrant in vitro and to tamoxifen in xenograft models. ARTN-stimulated resistance to tamoxifen and fulvestrant is mediated by increased BCL-2 expression. Conversely, depletion of endogenous ARTN by smallinterfering RNA or functional antagonism of ARTN by antibody enhanced the efficacy of antiestrogens. Tamoxifen decreased ARTN expression in tamoxifen-sensitive mammary carcinoma cells whereas ARTN expression was increased in tamoxifen-resistant cells and not affected by tamoxifen treatment. Antibody inhibition of ARTN in tamoxifen-resistant cells improved tamoxifen sensitivity. Functional antagonism of ARTN therefore warrants consideration as an adjuvant therapy to enhance antiestrogen efficacy in ER-positive mammary carcinoma.
Introduction
The pivotal role of estrogen in the etiology and progression of mammary carcinoma has been well defined (Yager and Davidson, 2006) . The biological effects of estrogen are mediated by two classical estrogen receptors (ERs): ERa and ERb. Estrogen-bound ER translocates to the nucleus and initiates gene transcription by binding to estrogen response element (ERE) in the promoter region of target genes. Alternatively, ER interacts with other transcription factors, indirectly modulating gene expression (Marino et al., 2006) . In addition to the nuclear action of ER, plasma membrane and cytoplasmlocalized ER activate multiple signaling pathways and exert rapid effects upon estrogen stimulation (Kampa et al., 2008; Levin and Pietras, 2008) .
Antiestrogens block the functions of ER and are widely used as systemic adjuvant therapy for ERpositive breast cancer (Johnston, 2005) . Tamoxifen competes with estrogen for ER binding, and functions as a selective estrogen receptor modulator with mixed antagonist and agonist activity dependent on tissue type (Osborne, 1998) . The pure ER antagonist fulvestrant (ICI 182780) downregulates ER protein, resulting in inhibition of ER signaling without any agonist effects (Dowsett et al., 2005) . Although antiestrogens have been proven to be an effective therapeutic approach for chemoprevention and treatment of mammary carcinoma (Abe et al., 1998) , both de novo resistance and acquired resistance to these drugs are major obstacles to control progression and metastasis (Musgrove and Sutherland, 2009) . Therefore, an improved understanding of the molecular basis of antiestrogen resistance and development of new strategies to increase the efficacy of antiestrogens are required.
Artemin (ARTN) belongs to the glial cell derived neurotrophic factor (GDNF) family of ligands (GFL) that include three other members: GDNF, neurturin and persephin. ARTN signaling is mediated through a multi-component receptor complex including the glycosylphosphatidylinositol-anchored GDNF family receptor a3 (GFRa3) or GFRa1 as one ligand binding component and RET receptor tyrosine kinase as one common signaling component (Airaksinen and Saarma, 2002; Carmillo et al., 2005) . We have recently identified an oncogenic role of ARTN in mammary carcinoma (Kang et al., 2009) . ARTN protein was detectable in 65% of mammary carcinoma and correlated to decreased overall survival (OAS) of breast cancer patients. Forced expression of ARTN in mammary carcinoma cells promoted anchorage-independent growth and enhanced migration and invasion, with resultant increased tumor growth in vivo. In addition, analysis of the cancer microarray database Oncomine revealed a significant association of ARTN expression with residual disease after chemotherapy (Kang et al., 2009) . Boulay et al. (2008) have recently reported the induction of RET and GFRa1 expression by estrogen treatment in ER-positive mammary carcinoma cells, indicating that GFL signaling may interact with estrogen signaling and potentially mediate some of the cellular functions of estrogen.
We report herein that ARTN is an estrogen-inducible gene that confers antiestrogen resistance in ER-positive mammary carcinoma cells.
Results

ARTN is an estrogen-inducible gene and is correlated with decreased survival in ER-positive breast cancer patients treated with tamoxifen
To determine the potential effect of estrogen on ARTN expression, we exposed ER-positive mammary carcinoma cells MCF-7 and T47D to 10 nM E 2 and determined the mRNA level of ARTN using quantitative PCR (qPCR). As shown in Figure 1a , E 2 stimulation resulted in increased ARTN expression as early as 6 h after treatment and the maximal E 2 -stimulated expression was observed after 72 h. An increase of ARTN protein in both MCF-7 and T47D cells on E 2 exposure was confirmed by western immunoblotting (Figure 1b) . E 2 -mediated upregulation of ARTN mRNA was ---+  -+  ---+  -+  TAM  --+  -+  ---+  -+ Figure 1 Artemin (ARTN) is an estrogen regulated gene and correlated with decreased survival in estrogen receptor (ER)-positive breast cancer patients treated with tamoxifen. (a) Human ER-positive mammary carcinoma cells MCF-7 and T47D were treated with 10 nM E 2 in phenol red-free medium containing 10% charcoal stripped-fetal bovine serum and total RNA from a triplicate sample was isolated at indicated time points. ARTN mRNA level was measured by qPCR. Fold changes were calculated relative to the samples at 0 time point. *Po0.05; **Po0.01 compared with 0 time point. (b) Western blot analysis of ARTN protein level in MCF-7 and T47D cells treated with either dimethyl sulfoxide (DMSO, vehicle) or 10 nM E 2 for 72 h. b-Actin was used as a loading control for cell lysate. (c) ER-positive MCF-7 and ER-negative BT549 cells were treated with either DMSO (vehicle), 10 nM E 2 , 1 mM tamoxifen or 100 nM fulvestrant for 72 h. ARTN mRNA level was measured by qPCR. *Po0.05 compared with vehicle control. (d) Kaplan-Meier analysis of the correlation of ARTN mRNA expression to distant metastasis-free survival (DMFS) and overall survival (OAS) in tamoxifen treated ER-positive breast cancer patients.
abrogated by tamoxifen and fulvestrant in MCF-7 cells (Figure 1c ). In contrast, neither estrogen nor antiestrogen treatment in ER-negative BT549 cells affected ARTN mRNA level (Figure 1c ). The modulation of ARTN expression by E 2 and antiestrogens in mammary carcinoma cells observed by qPCR was also confirmed by semi-quantitative RT-PCR using different ARTNspecific primers (Supplementary Figure S1a and 1b; Supplementary data 1).
Estrogen receptor status in breast cancer is a critical parameter to determine the response to antiestrogen therapy (Heldring et al., 2007) . On the basis of ER status, we evaluated ARTN mRNA expression in 20 breast cancer microarray data sets available in the cancer microarray database Oncomine (www.oncomine.org). The metaanalysis of these data sets revealed that ARTN expression was positively correlated with ER-positive status in mammary carcinoma (P ¼ 0.029, Supplementary Figure S2 ; Supplementary data 2).
We also determined whether ARTN expression in mammary carcinoma would affect the outcome of ER-positive patients treated with antiestrogen. We therefore analyzed ARTN mRNA expression in 68 patients with ER-positive mammary carcinoma treated with tamoxifen (Miller et al., 2005) . Kaplan-Meier analysis showed a highly significant correlation of increased ARTN mRNA expression to decreased distant metastasis-free survival (DMFS; hazard ratio: 2.5, 95% confidence interval: 1.1-5.5, P ¼ 0.02; Figure 1d ). To highlight the significant association of ARTN expression with poor DMFS outcome, we further split the cohort into three groups: lowest 33% (n ¼ 22), middle 33% (n ¼ 23) and highest 33% (n ¼ 23) of the expression level of ARTN (Supplementary Figure S3 ; Supplementary data 3). The group with the highest expression of ARTN had a particularly poor outcome, with 480% recurrence at 10 years. The P-value for this Kaplan-Meier analysis was 0.001. Increased ARTN expression was also significantly associated with decreased OAS (hazard ratio: 2.1, 95% confidence interval: 1.1-4.2, P ¼ 0.02; Figure 1d ).
ARTN enhanced ER transcriptional activity and function
To delineate the potential functional interaction between ARTN and ER signaling in mammary carcinoma cells, we first determined the effects of modulation of ARTN expression on ER transcriptional activity. The basal ER transcriptional activity (obtained in the absence of E 2 ) in MCF7-ARTN cells was 1.8-fold higher than MCF7-Vec cells. E 2 increased ERE-luciferase activity and forced expression of ARTN increased ER transcriptional activity with E 2 in an additive manner (Figure 2a ). The capacity of MCF7-Vec and MCF7-ARTN cells to form colonies in soft agar under estrogen-deprived or estrogen-replete conditions was examined. In the absence of estrogen stimulation, forced expression of ARTN resulted in a 1.7-fold increase of colony formation compared with the vector cells. E 2 promoted anchorage-independent growth and forced expression of ARTN enhanced the stimulatory effect of E 2 on colony formation in soft agar (Figure 2b ). We also showed by qPCR that forced expression of ARTN increased the expression of estrogen-responsive genes including progesterone receptor (PR), TFF1 and TFF3 in MCF7-ARTN cells compared with MCF7-Vec cells (Figure 2c) .
To examine the effects of depleted ARTN expression, we stably transfected two ARTN-specific small-interfering RNA (siRNA) plasmids into MCF-7 cells. Figure 2d shows that both the mRNA and protein expression levels of ARTN were efficiently decreased in the two stable MCF-7 cell lines, MCF7-siARTN A and MCF7-siARTN B, compared with the control MCF7-siCK cells. Depletion of endogenous ARTN by siRNA decreased ERE activity in both the absence and the presence of E 2 stimulation (Figure 2e ). Furthermore, siRNA-mediated depletion of ARTN decreased colony formation under estrogen-deprived conditions compared with vector cells and dramatically abrogated E 2 -stimulated anchorageindependent growth (Figure 2f ).
Forced expression of ARTN reduced antiestrogen sensitivity of mammary carcinoma cells As our data supported a potential functional interaction between ARTN and ER signaling, we assessed whether modulation of ARTN expression would affect the antiestrogen sensitivity of mammary carcinoma cells. In the absence of antiestrogen treatment, forced expression of ARTN in MCF-7 cells did not affect cell number in monolayer culture as described previously (Kang et al., 2009; Figure 3a) . However, in the presence of either tamoxifen or fulvestrant, MCF7-ARTN cells showed an increase in cell number compared with MCF7-Vec cells ( Figure 3a ). As the growth inhibitory effect of antiestrogen results from both inhibition of cell-cycle progression (Doisneau-Sixou et al., 2003) and induction of cell apoptosis (Bursch et al., 1996; Mandlekar and Kong, 2001 ), we determined S-phase entry by bromodeoxyuridine (BrdU) incorporation and apoptosis with Hoechst staining. Both tamoxifen and fulvestrant suppressed BrdU incorporation ( Figure 3b ) and increased apoptosis (Figure 3c ) in MCF7-Vec cells. Forced expression of ARTN significantly abrogated antiestrogen inhibition of cell-cycle progression ( Figure 3b ) and produced resistance to the apoptotic effect of antiestrogens (Figure 3c ).
We further compared the anchorage-independent growth of MCF7-Vec cells and MCF7-ARTN cells treated with antiestrogens using colony formation in soft agar. in vivo, we implanted MCF7-Vec or MCF7-ARTN cells into the mammary fat pad of immunodeficient mice, which were randomized to receive estrogen supplement combined with either tamoxifen or vehicle. As shown in Figure 4a , in mice supplemented with estrogen, tumors formed by MCF7-ARTN cells were 1.5-fold larger than those formed by MCF7-Vec cells, in confirmation of previously reported data (Kang et al., 2009) . Tamoxifen inhibited the growth of tumors derived from MCF7-Vec cells as expected (Sarkaria et al., 1993) . In contrast, forced expression of ARTN reduced tamoxifen efficacy, producing a tumor growth rate comparable with that observed in estrogen-stimulated MCF7-Vec tumors. BrdU incorporation and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assays were performed on tumor sections to quantify proliferation and apoptosis within the tumor at the time of termination of the experiment. As previously described (Kang et al., 2009) Forced expression of ARTN reduced ERb expression and increased BCL-2 expression in mammary carcinoma cells We next determined whether ARTN-induced antiestrogen resistance is due to modification of ER expression. We therefore compared ERa and ERb protein levels in MCF7-Vec and MCF7-ARTN cells. There was no difference in ERa expression between MCF7-Vec and MCF7-ARTN cells treated with vehicle, E 2 or antiestrogens (Figure 5a ), indicating that forced expression of ARTN did not affect ERa protein level. However, ERb expression was decreased in MCF7-ARTN cells under all examined conditions (Figure 5a ), indicating that ARTN decreased ERb expression in MCF-7 cells.
ARTN has been observed to promote mammary carcinoma cell survival under serum-reduced conditions (Kang et al., 2009 ). Several ARTN-regulated genes possessing anti-apoptotic function have been identified by qPCR, including BCL-2 whose expression was increased 8.4-fold in MCF7-ARTN cells compared with MCF7-Vec cells (Kang et al., 2009) . To elucidate the molecular mechanisms underlying ARTN-enhanced cell survival in response to antiestrogen treatment, we investigated the effect of forced expression of ARTN on the protein level of BCL-2 following antiestrogen treatment. As observed in Figure 5b , BCL-2 protein level was increased in MCF7-ARTN cells compared with MCF7-Vec cells under conditions of estrogen deprivation, estrogen stimulation or estrogen in combination with tamoxifen or fulvestrant. Estrogen increased BCL-2 expression whereas both tamoxifen and fulvestrant abrogated estrogen-stimulated BCL-2 expression in vector cells. Forced expression of ARTN prevented inhibition of BCL-2 expression by both tamoxifen and fulvestrant. To determine whether BCL-2 mediated ARTN-stimulated oncogenicity and antiestrogen resistance, we examined the anchorage-independent growth of MCF7-Vec and MCF7-ARTN cells in the presence of the BCL-2 inhibitor YC137 alone or in combination with tamoxifen or fulvestrant. As shown in Figure 5c , colony formation by MCF7-Vec cells was dramatically reduced by YC137, supportive of the reported function of BCL-2 in anchorage-independent growth (Zhang et al., 2003) . YC137 also significantly abrogated the ARTN enhancement of colony formation in soft agar, suggestive that BCL-2 is required for ARTN-stimulated anchorage-independent growth. Inhibition of BCL-2 also completely eliminated the protective effect of ARTN in response to treatment with tamoxifen and fulvestrant, suggestive that decreased antiestrogen sensitivity by forced expression of ARTN is mediated by increased BCL-2 expression. Consistent with the effect of depletion of ARTN by siRNA, a rabbit polyclonal antibody raised against ARTN enhanced the inhibitory effect of tamoxifen and fulvestrant on colony formation of MCF-7 cells. Rabbit anti-ARTN IgG alone possessed an inhibitory effect on anchorage-independent growth, with 35.6% reduction in colony formation in soft agar (Figure 6d ). Tamoxifen and fulvestrant produced 37.6 and 53.0% growth inhibition, respectively. The combination of anti-ARTN IgG with tamoxifen or fulvestrant produced 59.0 and 74.3% reduction, respectively. Similar changes were also observed after treatment with another polyclonal antibody against ARTN generated in chicken (Figures 6e and f) .
ARTN possesses a functional role in acquired tamoxifen resistance
To determine whether ARTN contributes to the acquisition of tamoxifen resistance in mammary carcinoma cells, we developed a tamoxifen-resistant MCF-7 cell line (designated as TAMR) as described in Materials and methods. The growth of tamoxifen-sensitive (TAMS) and TAMR cells was measured in estrogenfree medium containing 10 nM E 2 or 1 mM tamoxifen over a period of 7 days. TAMS cells retained the response to E 2 and were sensitive to tamoxifen. In contrast, TAMR cells grew faster and showed loss of response to E 2 and loss of tamoxifen sensitivity (Figure 7a ). We subsequently compared ARTN expression in TAMS and TAMR cells. In the absence of tamoxifen, both the mRNA and protein levels of ARTN 10 nM E 2 alone, or in combination with 1 mM tamoxifen or 100 nM fulvestrant in phenol red-free RPMI medium containing 1% charcoal stripped-fetal bovine serum (CS-FBS) for 72 h. Soluble whole cellular extracts were run on a sodium dodecyl sulfate-polyacrylamide gel electrophoresis and probed for ERa, ERb and BCL-2. b-Actin was used as loading control for whole-cell lysates. Protein level was determined by the Quantity One scanning system and densitometry software (Bio-Rad Laboratories Inc., Hercules, CA, USA), and then normalized to b-Actin in the same membrane. (c) Colony formation in soft agar: MCF7-Vec and MCF7-ARTN cells were cultured in 0.35% soft agar and treated with BCL-2 inhibitor YC137 at 1 or 5 mM alone or in combination with 1 mM tamoxifen or 100 nM fulvestrant for 10 days. The cell growth was measured using alamarBlue and presented as the percentage of vehicle-treated vector control cells. *Po0.05; **Po0.01; ***Po0.001 compared with vector control group for the same treatment.
were higher in TAMR cells compared with TAMS cells (Figure 7b ). Tamoxifen markedly reduced ARTN expression in TAMS cells. However, TAMR cells retained elevated ARTN expression at both the mRNA and protein levels in response to tamoxifen treatment (Figure 7b ).
To further determine the function of ARTN in TAMR cells, we measured the anchorage-independent growth of TAMR cells treated with tamoxifen alone or in combination with rabbit anti-ARTN IgG by colony formation in soft agar. Figure 7c shows that tamoxifen treatment did not affect colony formation of TAMR cells, thereby confirming the acquired tamoxifen resistance of these cells. Rabbit anti-ARTN IgG alone suppressed the basal growth of TAMR cells by 22.6% (Figure 7c ). Combined treatment with anti-ARTN IgG and tamoxifen resulted in reduction of colony formation by 32.9%, producing a similar effect to that observed in TAMS cells treated with tamoxifen alone. Similar results were also obtained with chicken anti-ARTN polyclonal antibody (Figure 7d ). Functional antagonism of ARTN by antibody also improved the sensitivity of TAMR cells to tamoxifen in monolayer culture (Supplementary Figure S5 ; Supplementary data 5).
Discussion
Compelling evidence supports the notion that growthfactor-driven signaling pathways fundamentally contribute (d-f) MCF-7 cells were cultured in soft agar and treated with 1 mM tamoxifen or 100 nM fulvestrant ± 400 mg/ml rabbit polyclonal IgG (d) or various concentrations of tamoxifen or fulvestrant ± 400 mg/ml chicken polyclonal IgY (e, f) against ARTN for 10 days. The cell growth in soft agar and 3D Matrigel was measured using alamarBlue and presented as the percentage of vehicle-treated vector control cells. *Po0.05; **Po0.01; ***Po0.001 compared with vector control group for the same treatment.
to the development of either de novo or acquired antiestrogen resistance (Massarweh and Schiff, 2006; Arpino et al., 2008) . Elevated expression of epidermal growth factor receptor (EGFR) and HER2 and activation of downstream signaling molecules such as p42/44 MAPK and phosphatidylinositol 3-kinase (PI3K)/AKT have been shown in antiestrogen-resistant cell lines and tumors (McClelland et al., 2001; Knowlden et al., 2003; Massarweh et al., 2008) . Clinical data also suggest that patients with increased expression of HER2 and EGFR in tumors have a poor outcome when treated with tamoxifen (Arpino et al., 2008) . Another tyrosine kinase receptor IGF-1R has been also suggested to be involved in acquired antiestrogen resistance in vitro, possibly through cross-talk with EGFR and HER2 . In addition, other growth factors or growth factor receptors such as PC cellderived growth factor (Tangkeangsirisin et al., 2004) and keratinocyte growth factor receptor (Rotolo et al., 2008) have been reported to confer tamoxifen resistance in human mammary carcinoma cells. In this study, we identified ARTN as a novel growth factor involved in antiestrogen resistance. As an estrogen-inducible gene, antiestrogen treatment reduced ARTN expression in ER-positive mammary carcinoma cells. However, in TAMR cells, ARTN expression was substantially increased and was not affected by tamoxifen treatment. The activity of IGF-1R, another estrogen-inducible gene, was also found to be fully restored in tamoxifenresistant tumors after undergoing initial reduction at (a) TAMS and TAMR cells were cultured in phenol red-free RPMI medium containing 10% charcoal stripped-fetal bovine serum (CS-FBS) for 3 days. Cells were then plated in 12-well plates at 20 000 cells per well and treated with either dimethyl sulfoxide (DMSO, vehicle), 10 nM E 2 or 1 mM tamoxifen over a period of 7 days. Cells were trypsinized and counted using Trypan blue. **Po0.01; ***Po0.001 compared with vehicle control. (b) TAMS and TAMR cells were cultured in phenol red-free RPMI medium containing 10% CS-FBS for 3 days and then treated with either DMSO (vehicle) or 1 mM tamoxifen for 72 h. Left: ARTN mRNA level was measured by qPCR. Right: soluble whole cellular extracts were run on a sodium dodecyl sulfate-polyacrylamide gel electrophoresis and probed for ARTN. b-Actin was used as a loading control. **Po0.01 compared with TAMS cells for the same treatment.
## Po0.01 compared with vehicle control. (c, d) TAMS and TAMR cells were cultured in soft agar and treated with 1 mM tamoxifen alone or in combination with 400 mg/ml rabbit polyclonal IgG (c) or 400 mg/ml chicken polyclonal IgY (d) against ARTN for 10 days. Cell growth was presented as the percentage of the group treated with vehicle and control IgG (c) or IgY (d). *Po0.05; **Po0.01 compared with the group treated with vehicle and control antibody. the tamoxifen-sensitive stage (Massarweh et al., 2008) . Interestingly, we found that ARTN expression was also increased upon IGF-1 stimulation in mammary carcinoma cells (unpublished observation), indicative of a potential interaction between ARTN and IGF-1R signaling. Furthermore, ARTN protein level has also been observed to be highly correlated to HER2 expression in breast tumor tissues (Kang et al., 2009) . Thus, ARTN signaling may integrate with HER2, IGF-1R and other growth factor signaling pathways, and contribute to the development of antiestrogen resistance in mammary carcinoma.
Estrogen receptor has been considered as the primary determinant of the clinical response to antiestrogen therapy (Heldring et al., 2007) . Forced expression of ARTN in MCF-7 cells did not affect ERa expression. Instead, decreased expression of ERb was observed in cells with forced expression of ARTN. Several reports have described loss of ERb during mammary tumorigenesis, supporting the potential role of ERb as a tumor suppressor (Park et al., 2003; Shaaban et al., 2003; Bardin et al., 2004; Rody et al., 2005) . ERb has been reported to modulate ERa activity and cellular response to estrogen (Hall and McDonnel, 1999; Pettersson et al., 2000) . Moreover, loss of ERb was observed to be associated with tamoxifen resistance whereas increase of ERb expression in MCF-7 cells enhanced the antiproliferative and apoptotic effect of antiestrogens (HodgesGallagher et al., 2008) . However, data regarding the association of ERb expression with clinical pathological parameters and antiestrogen responsiveness are still mixed (Speirs et al., 1999; O'Neill et al., 2004; Murphy and Watson, 2006) .
Although the mechanisms by which growth factor signaling pathways promote antiestrogen resistance have not been fully determined, cumulative experimental data suggest that activated growth factor signaling cross-talks with ER signaling resulting in ligandindependent or tamoxifen-induced ER activation with consequent promotion of tamoxifen-resistant tumor cell growth (Riggins et al., 2007; Arpino et al., 2008) . Our data also supported a potential functional interaction between ARTN and ER signaling through which ER activation upregulates ARTN expression and ARTN stimulation increases ER activity. As a secreted growth factor, ARTN presumably exerts its biological effects by binding to the receptor complex on the cell surface with consequent activation of multiple signal transduction pathways. Several growth factor receptor signaling pathways, such as HER2, EGFR and IGF-1R, have been reported to induce estrogen-independent ERa activation by phosphorylation of ER and increase ER transactivation domain AF-1 activity through MAPK and PI3K/AKT signaling pathways (Kato et al., 1995; Campbell et al., 2001; Fagan and Yee, 2008) . Indeed, ARTN stimulates AKT activity in endometrial carcinoma cells (Pandey et al., 2010) . We have also observed increased AKT phosphorylation in mammary carcinoma cells with forced expression of ARTN (paper in preparation). As discussed above, a potential functional interaction of ARTN with IGF-1R, HER2 signaling and other kinase signaling pathways may also contribute to ARTN-stimulated ER activity. However, the precise mechanisms by which ARTN promotes ER activation need to be determined.
Forced expression of ARTN also promotes tumor cell growth that is resistant to the pure antiestrogen fulvestrant, which exerts its effect by inducing ER degradation and abrogation of ER transcription (Dowsett et al., 2005) , implicating that ER-independent mechanisms for ARTN-stimulated oncogenicity may exist. Indeed, activated growth factor-initiated signaling pathways not only promote ER activation, but also function in an ER-independent manner (Nicholson et al., 2007) . For example, in the fulvestrant-resistant cell model, increased MAPK, AKT and NF-kB activities support the important role of growth factor signaling in the resistance to pure antiestrogens Riggins et al., 2005) . We have also previously reported that ARTN stimulates oncogenicity of ER-negative mammary carcinoma cells (Kang et al., 2009) .
Moreover, activated growth factor signaling can provide survival signals to protect from tamoxifenand fulvestrant-induced apoptosis (Kumar et al., 1996; Chung et al., 2002; Siddiqa et al., 2008) . We show herein that ARTN-stimulated resistance to antiestrogen is mediated by upregulation of BCL-2 protein expression. The estrogen-dependent expression of BCL-2 has been reported to contribute to the prosurvival effect of estrogen (Teixeira et al., 1995; Perillo et al., 2000) . Downregulation of BCL-2 is involved in antiestrogeninduced apoptosis and depletion of BCL-2 expression enhances sensitivity of breast cancer cells to tamoxifen (Diel et al., 1999; Zhang et al., 1999; Kim et al., 2005) . BCL-2 is positively associated with ERa expression (Elledge et al., 1997) whereas decreased BCL-2 expression has been observed after induction of ERb expression in T47D mammary carcinoma cells (Williams et al., 2008) , concordant with our observation that ERb is decreased and BCL-2 expression is increased by forced expression of ARTN.
In summary, this study has identified ARTN as a novel estrogen-regulated gene and showed that ARTN reduced the efficacy of antiestrogens in ER-positive mammary carcinoma cells. This effect may be mediated, at least in part, through reduced ERb expression level, enhanced ER transcriptional activity and increased expression of the anti-apoptotic protein BCL-2. Combination of antiestrogens and anti-ARTN antibody enhanced the efficacy of antiestrogens in mammary carcinoma cells and improved tamoxifen sensitivity in tamoxifen-resistant cells. Therefore, functional antagonism of ARTN warrants consideration as a novel adjuvant therapeutic approach for the treatment of ER-positive mammary carcinoma.
have previously generated the stable cell lines MCF7-ARTN and T47D-ARTN with forced expression of ARTN and their control cell lines MCF7-Vec and T47D-Vec, respectively. A detailed description of characterization of these cell lines has been reported previously (Kang et al., 2009) . To generate siRNA oligonucleotides targeting all five transcript variants of ARTN, we selected the DNA sequence 5 0 -AACAGCACCTG GAGAACCG-3 0 and 5 0 -AACTGGCCTGTACTCACTCAT-3 0 to construct siARTN A and siARTN B plasmids, respectively, using the pSilencer 2.1-U6 hygro vector (Ambion, Austin, TX, USA) according to the manufacturer's protocol. For estrogenfree cell culture, MCF-7 cells were cultured in phenol red-free RPMI medium supplemented with 10% dextran-coated charcoal-stripped fetal bovine serum (CS-FBS; Invitrogen, Carlsbad, CA, USA) for 3 days before estrogen or antiestrogen treatment.
The tamoxifen-resistant (TAMR) cell line was established as described by Shaw et al. (2006) . Briefly, the parental MCF-7 cells were continuously exposed for 6 months to 1 mM tamoxifen in phenol red-free RPMI medium containing 10% CS-FBS until the cells developed resistance to the growthinhibitory effect of tamoxifen. MCF-7 cells sensitive to tamoxifen, cultured in the same medium without tamoxifen, were designated as tamoxifen-sensitive (TAMS) cells.
Reagents b-Estradiol (E 2 ), tamoxifen and fulvestrant were purchased from Sigma-Aldrich (St Louis, MO, USA). Bcl-2 inhibitor YC137 was purchased from Calbiochem (San Diego, CA, USA). The chicken and rabbit anti-ARTN polyclonal antibodies were generated as described (Kang et al., 2009) .
Quantitative PCR and semiquantitative RT-PCR qPCR and semi-quantitative RT-PCR were performed as described previously (Kang et al., 2009) . ARTN primers used for qPCR were forward: 5 0 -ATGAACACTACAGTGGCTGA GG-3 0 and reverse: 5 0 -AGCTCCCATGAGTGAGTACAGG-3 0 .
Western blot analysis
Western blot analysis was performed as described previously (Liu and Lobie, 2007) using the following antibodies: goat anti-ARTN polyclonal antibody (R&D Systems, Minneapolis, MN, USA), rabbit anti-ERa, anti-ERb monoclonal antibodies (DakoCytomation, Glostrup, Denmark), mouse anti-BCL-2 monoclonal antibody (BD Pharmingen, San Diego, CA, USA) and mouse anti-b-ACTIN monoclonal antibody (Sigma, St Louis, MO, USA).
Luciferase assay Cells were plated in six-well plates and cultured in phenol red-free RPMI supplemented with 10% CS-FBS for 72 h before transfection. Total DNA (1 mg) per well containing 0.5 mg pGL2-ERE-luciferase plasmid and 0.5 mg pcDNA3 b-galactosidase reporter plasmid was transfected using FuGENE 6 reagent (Roche, Mannheim, Germany). Cells were then treated with either dimethyl sulfoxide (DMSO; vehicle) or 10 nM E 2 for 24 h. The cell lysate was used to quantify luciferase and b-galactosidase activities using the kit following the manufacturer's protocols (Promega, Madison, WI, USA).
Cell function assays
Total cell number, apoptosis, BrdU incorporation and 3D morphogenesis assays were performed as described (Kang et al., 2009) . Soft agar colony formation assay in 96-well plates was performed as described (Ke et al., 2004) with minor modification. Briefly, 5 Â 10 3 cells were seeded into 100 ml 0.35% agarose onto the 0.5% agarose base layer. Serumsupplemented medium (100 ml) containing drug or antibody was added on the top and changed every 3 days. After 10 days, alamarBlue was added (1:10 volume reagent; Invitrogen) and incubated at 37 1C for 4 h followed by measurement of fluorescence with excitation wavelength at 530 nm and emission wavelength at 590 nm.
Tumor xenograft in nude mice MCF7-Vec or MCF7-ARTN cells (3 Â 10 6 cells per site) were injected into the mammary fat pad of 3-to 4-week-old BALBc nu/nu mice (Shanghai Slaccas Co., Shanghai, China). E 2 pellets (1.7 mg; 60-day release) were implanted into the back 1 day before cell inoculation. The animals were then randomized to implant with either tamoxifen base pellets (5 mg; 60-day release) or placebo pellets (n ¼ 8 for each group). BrdU and TUNEL immunostainings were preformed as described (Pandey et al., 2008) .
Statistics
All experiments were repeated 3-4 times. All numerical data are expressed as mean±s.e.m. (standard error of the mean) from a representative experiment performed in triplicate, and statistical analyses were assessed by Student's t-test using Microsoft Excel XP.
Abbreviations ARTN, artemin; BrdU, bromodeoxyuridine; CS-FBS, charcoal stripped-fetal bovine serum; DMFS, distant metastasisfree survival; ER, estrogen receptor; ERE, estrogen response element; GDNF, glial cell derived neurotrophic factor; GFL, GDNF family of ligand; GFRa, GDNF family receptor-a; OAS, overall survival; PR, progesterone receptor; qPCR, quantitative PCR; siRNA, small-interfering RNA; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nickend labeling.
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